ViaCyte to Present at ISSCR 2016 Annual Meeting

SAN DIEGO, June 22, 2016 ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical-stage development, today announced two presentations at ISSCR 2016 Annual Meeting.  ISSCR 2016, the Global Stem Cell Event, is taking place June 22nd to 25th at Moscone West in San Francisco.

Details of the presentations are as follows:

Event:             Focus Session: Tools for Basic and Applied Stem Cell Biology – Panel discussion on pluripotent stem cell-based therapies
Speaker:         Dr. Kevin D’Amour, Vice President, Research, and Chief Scientific Officer
Date/Time:    June 22, 11:00 a.m. to 12:00 p.m. PDT

Poster:             In vitro generation of insulin producing cells with insulin secretion kinetics and mitochondrial respiration similar to adult human islets [Poster T2190] Speaker:         Dr. Alireza Rezania, Senior Director, Discovery
Date/Time:   June 23, 7:00 p.m. to 8:00 p.m., PDT

The work on insulin-producing cells with characteristics of mature human beta cells that is being reported in the poster presentation originated within the Janssen BetaLogics group.  In February 2016, the assets of the Janssen BetaLogics group were consolidated into ViaCyte.

“The results being presented at ISSCR demonstrate the continued progress we are making towards the development of important new treatments for insulin-dependent diabetes,” said Paul Laikind, PhD, President and CEO of ViaCyte.  “In particular, Dr. Rezania, who joined us as part of the BetaLogics asset consolidation, is reporting on advances that further bolster our leadership position in the field of stem cell-derived cell replacement therapy.

For more information about ViaCyte’s participation in industry events, please visit:

About ViaCyte

ViaCyte is a privately-held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to reduce the risk of hypoglycemia and diabetes-related complications.  ViaCyte’s product candidates are based on the derivation of pancreatic progenitor cells, which are then implanted in a durable and retrievable encapsulation device.  Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels.  ViaCyte has two products in development.  PEC-Direct product candidate delivers the pancreatic progenitor cells in a non-immunoprotective device and is being developed for type 1 diabetes patients that have severe hypoglycemic episodes, extreme glycemic lability, and/or impaired awareness of hypoglycemia.  The PEC-EnCap (formerly VC-01™) product candidate delivers pancreatic progenitor cells in an immunoprotective device and is currently being evaluated in a Phase 1/2 trial in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function.  ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia.  The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.

For more information on the clinical trial, called STEP ONE, please visit